- Home
- Forums
- Groups
- Maps
- Resources
- We Have / We Need
- Cholera
- Water Filtration - Homemade ORS
- CTC - Development and Operation
- Cholera - Clinical Presentation and Management
- Cholera Kit - Medical Supplies Guidelines
- Haiti Cholera Training Materials
- Origins of Epidemic
- Posters - Clinical Presentation and Management
- Video - The Story of Cholera - Andeyo Version
- Video - The Story of Cholera - English
- Video - The Story of Cholera - Haitian Creole
- Archive
You are here
Immunocompromised people may get less protection from mRNA vaccines: new study
Primary tabs
Wed, 2021-11-03 17:57 — mike kraft
Two Doses of mRNA COVID Vax Not Enough for the Immunosuppressed Largest study yet supports extra doses for these patients medpagetoday

COVID-19 vaccines worked fairly well in keeping immunocompromised patients out of the hospital from the infection, but still less than for those with a competent immune system, a study showed.
After two vaccine doses, immunocompromised patients saw 77% vaccine effectiveness (95% CI 74%-80%) against hospitalization for confirmed COVID-19, with a 3.9% rate of SARS-CoV-2 test positivity in hospital compared with 11.8% among those who were unvaccinated.
Effectiveness was similar between Moderna and Pfizer for these patients but did vary by type of immunocompromise, ranging from 59% for solid organ or stem cell transplant recipients to 81% in those with a rheumatologic or inflammatory condition.
For immunocompetent patients in hospital, vaccine effectiveness came in at the expected 90% (95% CI 89%-91%), with 3.8% versus 24.8% positive tests with and without vaccination, respectively, reported Peter J. Embi, MD, of the Regenstrief Institute, a research organization affiliated with the Indiana University School of Medicine in Indianapolis, and colleagues in the Morbidity and Mortality Weekly Report.
Their study of some 89,000 hospitalizations for COVID-like illness accounted for age, local virus circulation in patients' community, and other factors.
"Immunocompromised persons benefit from and should receive COVID-19 vaccines," the researchers concluded, saying that their findings of lower effectiveness compared with the immune-competent supported recent CDC recommendations for this high-risk population. ...
ALSO SEE: Immunocompromised people may get less protection from mRNA vaccines: CDC
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -
Recent Comments